Vis enkel innførsel

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

dc.contributor.authorChristensen, Ingrid Egeland
dc.contributor.authorJyssum, Ingrid
dc.contributor.authorTveter, Anne Therese
dc.contributor.authorSexton, Joseph
dc.contributor.authorTran, Trung
dc.contributor.authorMjaaland, Siri
dc.contributor.authorKro, Grete Anette Birkeland
dc.contributor.authorKvien, Tore Kristian
dc.contributor.authorWarren, David
dc.contributor.authorJahnsen, Jørgen
dc.contributor.authorMunthe, Ludvig Andre
dc.contributor.authorHaavardsholm, Espen A.
dc.contributor.authorVaage, John T.
dc.contributor.authorGrødeland, Gunnveig
dc.contributor.authorLund-Johansen, Fridtjof
dc.contributor.authorJørgensen, Kristin Kaasen
dc.contributor.authorSyversen, Silje Watterdal
dc.contributor.authorGoll, Guro Løvik
dc.contributor.authorProvan, Sella Aarrestad
dc.date.accessioned2022-11-28T11:50:47Z
dc.date.available2022-11-28T11:50:47Z
dc.date.created2022-11-16T15:13:48Z
dc.date.issued2022
dc.identifier.citationBMC Medicine. 2022, 20 (1), 1-13.en_US
dc.identifier.issn1741-7015
dc.identifier.urihttps://hdl.handle.net/11250/3034461
dc.description.abstractThe durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not known. The aim of this study was to compare the persistence of anti-Spike antibodies following two-dose SARS-CoV-2 vaccination between IMID patients and healthy controls and to identify factors associated with antibody decline.en_US
dc.language.isoengen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectSARS-CoV-2 vaccineen_US
dc.subjectCOVID-19en_US
dc.subjectSerologic responseen_US
dc.subjectRheumatic diseasesen_US
dc.subjectInfammatory bowel diseaseen_US
dc.titleThe persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort studyen_US
dc.title.alternativeThe persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.subject.nsiVDP::Matematikk og Naturvitenskap: 400en_US
dc.source.pagenumber1-13en_US
dc.source.volume20en_US
dc.source.journalBMC Medicineen_US
dc.source.issue1en_US
dc.identifier.doi10.1186/s12916-022-02587-8
dc.identifier.cristin2075057
dc.relation.projectNorges forskningsråd: 328657en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail
Filnavn:
Christensen et al 2022.pdf
Størrelse:
1.660Mb
Format:
PDF
Åpne

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal